retatrutide side effects clinical trial results 2024 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Eli Lilly infiltrates anti-obesity market

A secondary objective was to evaluate the methodological approaches used in these studies to identify best practices for investigating and interpreting the effects of GLP-1 RAs on neuroaffective responses to motivationally relevant stimuli

By understanding what to expect and how to manage muscle cramps, you can navigate this potential side effect while maximising the benefits of your Mounjaro treatment

This can lead to an overall improvement in comfort and functioning in daily life

The GLP-1 market is now worth more than $60 billion annually

Ready to find your balance with food

On October 2, 2024, however, FDA determined that the shortage of tirzepatide injection had been resolved, and compounders already have been required to adjust their practices to comply with FDAs requirements for what can be legally compounded outside of a drug shortage